Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Second Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation

NCT01102114 is registered in ClinicalTrials.gov with Nabi Biopharmaceuticals as lead sponsor.

NCT NCT01102114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01102114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Second Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation
Lead sponsor
Nabi Biopharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2010
Completion date
November 30, 2011
Enrollment
1,000 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation